| 7.8765 0.167 (2.16%) | 10-24 14:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.65  |
1-year : | 11.27 |
| Resists | First : | 8.26 |
Second : | 9.65 |
| Pivot price | 5.79 |
|||
| Supports | First : | 5.62 |
Second : | 3.99 |
| MAs | MA(5) : | 7.03 |
MA(20) : | 5.43 |
| MA(100) : | 3.78 |
MA(250) : | 3.36 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 87.2  |
D(3) : | 89.1 |
| RSI | RSI(14): 80.7 |
|||
| 52-week | High : | 8.26 | Low : | 1.98 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GNLX ] has closed above the upper band by 2.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 332.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.05 - 8.08 | 8.08 - 8.11 |
| Low: | 6.24 - 6.27 | 6.27 - 6.3 |
| Close: | 7.64 - 7.71 | 7.71 - 7.76 |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Fri, 24 Oct 2025
Maxim Group Maintains Genelux(GNLX.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
Tue, 21 Oct 2025
Lake Street Initiates Coverage of Genelux (GNLX) with Buy Recommendation - Nasdaq
Tue, 21 Oct 2025
GNLX: Lake Street Initiates Coverage with 'Buy' Rating and $16 P - GuruFocus
Tue, 21 Oct 2025
Lake Street Capital Markets initiates Genelux stock with Buy rating - Investing.com
Wed, 03 Sep 2025
Genelux Corp. Lowers Stock Option Exercise Prices - TipRanks
Tue, 02 Sep 2025
Immuno-Oncology Pioneer Genelux Leadership Team Featured at H.C. Wainwright Global Investment Conference - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 13.2 (%) |
| Held by Institutions | 20.3 (%) |
| Shares Short | 2,210 (K) |
| Shares Short P.Month | 2,120 (K) |
| EPS | -0.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52.2 % |
| Return on Equity (ttm) | -98.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -9.32 |
| PEG Ratio | 0 |
| Price to Book value | 12.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|